The enactment of statewide medicinal cannabis laws is associated with a quantifiable decline in the use of traditional prescription drugs, according to data published in the July edition of the scientific journal Health Affairs.
Investigators at the University of Georgia assessed the relationship between medical marijuana legalization laws and physicians’ prescribing patterns in 17 states over a three-year period (2010 to 2013). Specifically, researchers assessed patients’ consumption of and spending on prescription drugs approved under Medicare Part D in nine domains: anxiety, depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders, and spasticity.
Authors reported that prescription drug use fell significantly in seven of the nine domains assessed.
“Generally, we found that when a medical marijuana law went into effect, prescribing for FDA-approved prescription drugs under Medicare Part D fell substantially,” investigators reported. “Ultimately, we estimated that nationally the Medicare program and its enrollers spent around $165.2 million less in 2013 as a result of changed prescribing behaviors induced by … jurisdictions that had legalized medical marijuana.”
Investigators estimated that prescription drug savings would total more than $468 million annually were cannabis therapy to be accessible in all 50 states.
They concluded, “Our findings and existing clinical literature imply that patients respond to medical marijuana legislation as if there are clinical benefits to the drug, which adds to the growing body of evidence suggesting that the Schedule I status of marijuana is outdated.”
An abstract of the study, “Medical marijuana laws reduce prescription medication use in Medicare Part D,” is available online here.
The Secretary of State’s office confirmed yesterday that proponents of the measure, The Adult Use Marijuana Act, collected over 600,000 signatures from registered voters to place the initiative on the ballot.
Passage of the Act would permit adults to legally grow (up to six plants) and possess personal use quantities of cannabis (up to one ounce of flower and/or up to eight grams of concentrate) while also licensing commercial cannabis production and retail sales. The measure prohibits localities from preventing responsible adults from possessing and cultivating cannabis for non-commercial purposes in the privacy of their own homes. The initiative language specifies that it is not intended to “repeal, affect, restrict, or preempt … laws pertaining to the Compassionate Use Act of 1996.”
Sixty percent of likely California voters say that they intend to vote for the initiative this fall, according to a February 2016 Probolsky Research poll.
The AUMA is endorsed by a host of statewide and national organizations, including the ACLU of California, the California Democratic Party, the California Medical Association, California Lt. Gov. Gavin Newsom, the California NAACP, the Drug Policy Alliance, Students for Sensible Drug Policy, and NORML.
California is one of several states where voters will be going to the polls in November to decide on statewide marijuana law reform measures. Separate legalization measures have either qualified for the ballot or are anticipated to appear on the ballot in Arkansas (medical), Arizona, Florida (medical), Maine, Massachusetts, Missouri (medical), and Nevada. A Michigan legalization initiative effort is presently in litigation.
As predicted, 2016 is turning out to a historic year for the marijuana legalization movement. With three statewide initiatives already cleared for the November ballot (Florida, Nevada, Maine) and several other initiative campaigns awaiting certification, there has never been a greater need for grassroots marijuana activism. From gathering signatures and making volunteer recruitment calls, to data entry and talking face to face with voters, there is still plenty of work to be done. To get involved today, simply follow the three easy steps below!
First, please consider becoming a member of our organization (NORML Membership). In addition to being a part of the nation’s longest serving marijuana law reform group and getting a great membership package, we have compiled an extensive collection of fact-based information that you can use to support your efforts as you engage lawmakers in your community. Regardless of the point you’re trying to make (recreational, medical, hemp, CBD, etc.) you’ll find recent studies, articles and other resources that will help reinforce your argument (NORML Library).
Second, if there isn’t already a NORML affiliate in your community (Chapter Locator), I encourage you to begin the process of forming your own chapter. For more than 40 years, NORML affiliates and chapters have been leading reform conversations on the local and state level, and they continue to be the driving force behind policy decisions regarding marijuana. If this is something that you’d like to be a part of, please take a few minutes to review NORML’s new Chapter Starter Packet. It will serve as your number one resource as you get started. If you need help finding others to join you, I’m happy to help connect you with people in your area.
Third, start contacting your local, state and federal representatives about pending marijuana-related legislation by using our online Action Alert Center. We’re constantly monitoring dozens of marijuana-related bills from around the country so we’re able to provide you with the most up-to-date legislative alerts and talking points. In addition to advocating for marijuana law reform using the legislative process, we also welcome the opportunity to work with your organization to draft a municipal ordinance, similar to the ones recently adopted by local governments in Ohio and Florida.
I look forward to working with you to establish a new community of marijuana activists in your state! For more information about forming a NORML chapter or getting involved with marijuana law reform efforts, please email KevinM@NORML.org or visit NORML.org.
The passage of statewide laws regulating the consumption of cannabis by adults and/or qualified patients is not associated with increased rates of teen marijuana use, according to a statistical analysis of results from the Centers for Disease Control and Prevention’s 2015 Youth Risk Behavior Survey.
CDC data reports that the percentage of high-schoolers ever reporting having used cannabis fell from an estimated 43 percent in 1995 to just under 39 percent in 2015. The percentage of teens currently using cannabis (defined as having used marijuana at least once in the past 30 days) also declined during this same period, from 25 percent in 1995 to just under 22 percent in 2015.
During this time period, two-dozen states enacted statutes permitting qualified patients to consume cannabis, and four states enacted laws permitting the commercial production and retail sale of marijuana to adults.
The Youth Risk Behavior Survey results are consistent with those of numerous other studies — such as those here, here, here, here, here, here, here, here, here, and here — finding that changes in cannabis’ legal status are not associated with increased use among adolescents.
Rising rates of medical cannabis use among Canadian military veterans is associated with a parallel decline in the use of prescription opiates and benzodiazepenes, according to federal data recently provided to The Globe and Mail.
According to records provided by Veterans Affairs Canada, the number of veterans prescribed benzodiazepines (e.g. Xanax, Ativan, and Valium) fell nearly 30 percent between 2012 and 2016, while veterans’ use of prescription opiates declined almost 17 percent. During this same period, veterans seeking federal reimbursements for prescription cannabis rose from fewer than 100 total patients to more than 1,700.
Canadian officials legalized the use of cannabis via prescription in 2001.
While the data set is too small to establish cause and effect, the trend is consistent with data indicating that many patients substitute medical cannabis for other prescription drugs, especially opiates.
Prior assessments from the United States report that incidences of opioid-related addiction, abuse, and mortality are significantly lower in jurisdictions that permit medicinal cannabis access as compared to those states that do not.